CLINICAL_TRIALS ClinicalTrials.gov record update

Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00619268
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:22.067170+00:00
Published At: 2013-02-15T00:00:00+00:00
Record Updated At: 2013-02-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-02-15"
protocolSection.identificationModule.nctId: "NCT00619268"
protocolSection.identificationModule.officialTitle: "Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel\u00ae (Temsirolimus) and Avastin\u00ae (Bevacizumab) Versus Sutent\u00ae (Sunitinib) and Versus a Combination of Avastin\u00ae (Bevacizumab) and Rof\u00e9ron\u00ae (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.